Literature DB >> 14672622

Hexokinase II and VEGF expression in liver tumors: correlation with hypoxia-inducible factor 1 alpha and its significance.

Seiichi Yasuda1, Shigeki Arii, Akira Mori, Naoki Isobe, Weige Yang, Hideaki Oe, Akihisa Fujimoto, Yoshikuni Yonenaga, Hiromi Sakashita, Masayuki Imamura.   

Abstract

BACKGROUND/AIMS: We analyzed the expressions of hexokinase II (HK II), a key enzyme in glycolysis, and VEGF in hepatocellular carcinoma (HCC) and metastatic liver cancer in relation to tumor vascularity, and the participation of hypoxia-inducible factor-1 (HIF-1) was studied.
METHODS: A real-time quantitative reverse transcription-polymerase chain reaction was performed to examine the HK II and VEGF mRNA expression. Expression of HIF-1 alpha and HK II protein, and microvessel density (MVD) were examined immunohistochemically.
RESULTS: MVD was significantly higher in HCCs than in metastatic liver cancers, and VEGF mRNA expression was positively correlated only with MVD of HCCs. HK II mRNA expression was significantly higher in metastatic liver cancers, however, some cases of HCC pretreated with transcatheter arterial embolization (TAE) showed marked HK II mRNA expression. Both HIF-1 alpha and HK II protein expressions were co-localized in the cancer cells near necrosis, and the intensity of HIF-1 alpha protein expression was significantly correlated with HK II mRNA expression in both tumors.
CONCLUSIONS: These results suggest that, in metastatic liver cancers, glycolysis induced by HIF-1 is the predominant energy source under the hypoxic environment and, at least in some TAE-pretreated HCC cases, cancer cells obtain energy for growth by switching the metabolic profile to glycolysis through HIF-1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14672622     DOI: 10.1016/s0168-8278(03)00503-8

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  46 in total

1.  Reduced survival of patients with hepatocellular carcinoma expressing hexokinase II.

Authors:  Lei Gong; Zhuqingqing Cui; Pengcheng Chen; Hui Han; Jirun Peng; Xisheng Leng
Journal:  Med Oncol       Date:  2011-01-30       Impact factor: 3.064

2.  Vascularization of rat pituitary autografts.

Authors:  Matilde Lombardero; Andres Quintanar-Stephano; Sergio Vidal; Eva Horvath; Kalman Kovacs; Ricardo V Lloyd; Bernd W Scheithauer
Journal:  J Anat       Date:  2006-05       Impact factor: 2.610

Review 3.  Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma.

Authors:  Shinji Tanaka; Shigeki Arii
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.402

4.  Antitumoral activity of rapamycin mediated through inhibition of HIF-1alpha and VEGF in hepatocellular carcinoma.

Authors:  Wei Wang; Wei-Dong Jia; Ge-Liang Xu; Zhi-Hua Wang; Jian-Sheng Li; Jin-Liang Ma; Yong-Sheng Ge; Sheng-Xue Xie; Ji-Hai Yu
Journal:  Dig Dis Sci       Date:  2008-12-04       Impact factor: 3.199

5.  Hexokinase II in CD133+ and CD133- hepatoma BEL-7402 Cells.

Authors:  Lei Gong; Zhuqingqing Cui; Xin Yu; Yuhua Wei; Jirun Peng; Xisheng Leng
Journal:  Pathol Oncol Res       Date:  2011-09-10       Impact factor: 3.201

Review 6.  18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization.

Authors:  Hossein Jadvar; Abass Alavi; Sanjiv S Gambhir
Journal:  J Nucl Med       Date:  2009-10-16       Impact factor: 10.057

7.  Regulation of the Warburg effect in early-passage breast cancer cells.

Authors:  Ian F Robey; Renu M Stephen; Kathy S Brown; Brenda K Baggett; Robert A Gatenby; Robert J Gillies
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

8.  Functional domains of yeast hexokinase 2.

Authors:  Rafael Peláez; Pilar Herrero; Fernando Moreno
Journal:  Biochem J       Date:  2010-11-15       Impact factor: 3.857

9.  Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer.

Authors:  Rafael Duran; Sahar Mirpour; Vasily Pekurovsky; Shanmugasundaram Ganapathy-Kanniappan; Cory F Brayton; Toby C Cornish; Boris Gorodetski; Juvenal Reyes; Julius Chapiro; Rüdiger E Schernthaner; Constantine Frangakis; MingDe Lin; Jessica D Sun; Charles P Hart; Jean-François Geschwind
Journal:  Clin Cancer Res       Date:  2016-07-20       Impact factor: 12.531

10.  Distinct temporospatial expression patterns of glycolysis-related proteins in human hepatocellular carcinoma.

Authors:  Katjana Daskalow; David Pfander; Wilko Weichert; Nadine Rohwer; Armin Thelen; Peter Neuhaus; Sven Jonas; Bertram Wiedenmann; Christoph Benckert; Thorsten Cramer
Journal:  Histochem Cell Biol       Date:  2009-04-07       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.